Crestline Management, LP Cogent Biosciences, Inc. Transaction History
Crestline Management, LP
- $1.88 Billion
- Q3 2024
A detailed history of Crestline Management, LP transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Crestline Management, LP holds 369,763 shares of COGT stock, worth $3.38 Million. This represents 0.21% of its overall portfolio holdings.
Number of Shares
369,763
Previous 326,070
13.4%
Holding current value
$3.38 Million
Previous $2.75 Million
45.31%
% of portfolio
0.21%
Previous 0.22%
Shares
3 transactions
Others Institutions Holding COGT
# of Institutions
171Shares Held
113MCall Options Held
56.7KPut Options Held
40.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$95.6 Million0.31% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.24MShares$84.4 Million8.19% of portfolio
-
Commodore Capital LP New York, NY7.54MShares$68.8 Million6.92% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$66.5 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$63.6 Million9.76% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $600M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...